Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek

Vertex Pharmaceuticals and NHS England have reached a reimbursement agreement for Alyftrek, a once-daily triple therapy for cystic fibrosis (CF) patients in England125.

Alyftrek is indicated for patients aged 6 and older with at least one F508del mutation—or another responsive mutation—in the CFTR gene235.

The agreement follows a positive final draft recommendation from the National Institute for Health and Care Excellence (NICE)235.

Alyftrek is Vertex’s fifth cystic fibrosis medicine and features a combination of deutivacaftor, tezacaftor, and vanzacaftor23.

Pivotal studies indicate Alyftrek may offer even better outcomes than previous Vertex therapies such as Kaftrio35.

England is among the first countries to secure broad access for eligible patients, with ongoing discussions to expand availability throughout the EU35.

Specific financial terms of the deal were not disclosed1.

Sources:

1. https://www.geneonline.com/vertex-pharmaceuticals-and-nhs-england-reach-agreement-to-provide-alyftrek-for-cystic-fibrosis-treatment/

2. https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025

3. https://pharmatimes.com/news/nhs-england-secures-access-to-new-cystic-fibrosis-treatment-alyftrek/

5. https://healtheconomics.com/nhs-england-secures-access-to-new-cystic-fibrosis-treatment/